

Xynomic Pharma completes series B financing

June 3, 2018 | News

The Series B proceeds will be used to initiate eight clinical trials, four of which are pivotal, in the next 12 months.



Xynomic Pharma, a clinical stage US-China oncology drug development company, recently announced that it has completed Series B Crossover financing, led by experienced healthcare investors Northern Light Venture Capital, Zhongshan Bison Healthcare Investment Limited and Hakim Unique Internet Company Limited.

All existing investors including Prosperico Ventures and Mr. Yinglin Mark Xu, Xynomic Pharma's founder and Chairman, participated in this round of financing.

The Series B proceeds will be used to initiate eight clinical trials, four of which are pivotal, in the next 12 months.

Xynomic has also launched its own R&D Innovation Centre in Shanghai in May 2018 to discover and develop small molecule oncology drugs focused on kinase inhibition, immuno-oncology and epigenetic modification. The centre is designed to have fully integrated in-house capabilities from lead identification to IND enabling studies.